Featured Publications

Found 8 results

Filters: Keyword is Humans [Clear All Filters]

2017

Silver RT, Barel AC, Lascu E, Ritchie EK, Roboz GJ, Christos PJ, Orazi A, Hassane DC, Tam W, Cross NCP. 2017. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.. Cancer. 123(14):2680-2687.

Kvasnicka HMichael, Orazi A, Thiele J, Barosi G, Bueso-Ramos CE, Vannucchi AM, Hasserjian RP, Kiladjian J-J, Gianelli U, Silver R et al.. 2017. European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.. Am J Hematol. 92(10):1062-1067.

2016

Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E et al.. 2016. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.. Clin Lymphoma Myeloma Leuk. 16(5):297-303.

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R et al.. 2016. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.. J Natl Cancer Inst. 108(7)

Hehlmann R, Saußele S, Voskanyan A, Silver RT. 2016. Management of CML-blast crisis.. Best Pract Res Clin Haematol. 29(3):295-307.

Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian J-J, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL et al.. 2016. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.. Leukemia. 30(5):1018-24.

2008